ProCE Banner Activity

Phase III TULIP: vic-Trastuzumab Duocarmazine vs Physician’s Choice Treatment in Previously Treated HER2+ Advanced Breast Cancer

Slideset Download
Conference Coverage
vic-Trastuzumab duocarmazine, a novel antibody–drug conjugate, improved median PFS vs physician’s choice therapy in pretreated HER2+ locally advanced or metastatic breast cancer.

Released: September 28, 2021

Expiration: September 27, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Exelixis, Inc.

Ipsen Biopharmaceuticals Inc